Onconetix (ONCO) Restructuring Costs (2022)
Onconetix (ONCO) posted quarterly Restructuring Costs of $800000.0 for Q3 2022.
Onconetix (ONCO) Restructuring Costs (2022) Analysis & Trends
Onconetix (ONCO) has reported Restructuring Costs for 1 consecutive years, with $800000.0 the latest figure, recorded in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Onconetix | 1.46 Mn | -4.49 Mn | 4,303.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 800,000.00 |